Drug intelligence / Profile preview

OBI-898

Development stage: Discontinued
Lead developer: OBI Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

OBI-898 is a monoclonal antibody developed by OBI Pharma that targets Stage-specific embryonic antigen-4 (SSEA-4), a glycolipid antigen frequently overexpressed on the surface of various cancer cells. Designed as an immuno-oncology therapeutic, OBI-898 was intended to treat a range of neoplasms by inhibiting SSEA-4-mediated pathways. However, OBI Pharma discontinued the development of OBI-898 in 2021 after preclinical studies, including drug metabolism and pharmacokinetics (DMPK) and toxicology assessments, failed to meet the required criteria for advancing to clinical trials.

Targets

SSEA-4 (Stage-specific embryonic antigen-4)

Beyond the preview

Go deeper on OBI-898.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBI-898.

Explore the full profile